NIH Parkinson's Disease Repurposing Program

📖 Wiki Page

institution810 wordssynced 2026-04-02

Introduction

<div class="infobox infobox-institution">
{| class="infobox-table"
| colspan="2" class="infobox-header" | NIH Parkinson's Disease Repurposing Program
|-
| Established | 2019
|-
| Lead Institution | National Institute of Neurological Disorders and Stroke (NINDS)
|-
| Type | Government-Funded Drug Repurposing Initiative
|-
| Focus | Accelerating disease-modifying therapies for Parkinson's disease
|-
| Website | [clinicaltrials.gov](https://clinicaltrials.gov)
|}
</div>

Overview

flowchart TD institutions_nih_parkinsons_re["NIH Parkinsons Disease Repurposing Program"] institutions_nih_parkinsons_re["Introduction"] institutions_nih_parkinsons_re -->|"related to"| institutions_nih_parkinsons_re style institutions_nih_parkinsons_re fill:#81c784,stroke:#333,color:#000 institutions_nih_parkinsons_re["infobox-institution"] institutions_nih_parkinsons_re -->|"related to"| institutions_nih_parkinsons_re style institutions_nih_parkinsons_re fill:#81c784,stroke:#333,color:#000 institutions_nih_parkinsons_re["infobox-table"] institutions_nih_parkinsons_re -->|"related to"| institutions_nih_parkinsons_re style institutions_nih_parkinsons_re fill:#81c784,stroke:#333,color:#000 institutions_nih_parkinsons_re["infobox-header"] institutions_nih_parkinsons_re -->|"related to"| institutions_nih_parkinsons_re style institutions_nih_parkinsons_re fill:#81c784,stroke:#333,color:#000 style institutions_nih_parkinsons_re fill:#4fc3f7,stroke:#333,color:#000

...

Introduction

Overview

Mermaid diagram (expand to render)

The NIH Parkinson's Disease Repurposing Program is a coordinated federal initiative to identify existing drugs that can be repurposed for Parkinson's disease therapy development. Led by the [National Institute of Neurological Disorders and Stroke](/institutions/nih-ninds) (NINDS) in collaboration with the [National Institute on Aging](/institutions/nih-nia) (NIA), this program leverages the NIH's unique position to facilitate rapid clinical testing of approved compounds for new indications.

The program emerged from the recognition that the drug development pipeline for Parkinson's disease lacks sufficient disease-modifying therapies, and that drug repurposing offers a faster path to clinical translation given known safety profiles of existing drugs.

Program Structure

NIH NINDS Leadership

Parkinson's Disease Research Program: Funding clinical trials for PD therapeutics
Clinical Trials Infrastructure: Support for multi-site trials across the Parkinson's community
Data Sharing Initiatives: Open science approaches to accelerate research

NIH NIA Collaboration

Aging-Related Mechanisms: Understanding how aging intersects with PD pathogenesis
Alzheimer's Disease Drug Repurposing: Shared learnings from AD repurposing efforts
Biomarker Development: Common biomarker platforms for neurodegenerative diseases

Repurposing Pipeline

Phase I: Compound Identification

The program screens existing compounds based on:

| Criterion | Description |
|-----------|-------------|
| Mechanistic Rationale | Drugs targeting PD-relevant pathways |
| [Blood-Brain Barrier](/entities/blood-brain-barrier) Penetration | CNS penetration for neuronal targets |
| Known Safety Profile | Established human safety data |
| Preclinical Evidence | Animal model support for neuroprotection |

Phase II: Preclinical Validation

Promising compounds undergo:

In vitro assays targeting PD mechanisms ([alpha-synuclein](/proteins/alpha-synuclein) aggregation, mitochondrial dysfunction, neuroinflammation)
In vivo validation in PD animal models
Dose-response studies for neuroprotective effects
Pharmacokinetic optimization for CNS delivery

Phase III: Clinical Translation

Clinical trial phases include:

Phase IIa: Safety and tolerability in PD patients
Phase IIb: Proof-of-concept efficacy signals
Phase III: Definitive efficacy trials

Key Repurposed Drugs in Program

GLP-1 Receptor Agonists

The NIH has supported multiple clinical trials of [GLP-1 receptor](/entities/glp1-receptor) agonists for Parkinson's disease:

| Drug | Trial Phase | Status | Mechanism |
|------|-------------|--------|-----------|
| Exenatide | Phase III | Completed | GLP-1R activation, neuroprotection |
| Liraglutide | Phase II | Completed | GLP-1R activation, anti-inflammatory |
| Semaglutide | Phase II/III | Ongoing | GLP-1R activation, mitochondrial function |

Clinical Evidence:

Exenatide: Phase II trial showed significant motor improvement in PD patients
NIH-funded studies have demonstrated neuroprotective effects in preclinical models
Ongoing Phase III trials to confirm disease-modifying potential

Tyrosine Kinase Inhibitors

| Drug | Target | PD Rationale |
|------|--------|--------------|
| Nilotinib | BCR-ABL, c-KIT | [Autophagy](/entities/autophagy) induction, alpha-synuclein clearance |
| Dasatinib | BCR-ABL | Senolytic effects, anti-inflammatory |

NIH-Supported Trials:

Nilotinib Phase II trial demonstrated safety and preliminary efficacy
Combination dasatinib/quercetin senolytic trial in development

Anti-Inflammatory Agents

| Drug | Mechanism | Trial Status |
|------|-----------|--------------|
| Minocycline | Microglial inhibition | Phase II completed |
| Ibuprofen | COX inhibition | Observational studies |

Collaboration Model

Academic Partnerships

The program works with leading research institutions:

[Michael J. Fox Foundation](/institutions/michael-j-fox-foundation)](/institutions)
[Parkinson's Foundation](/institutions/parkinsons-foundation)
Academic medical centers with PD research programs

Pharmaceutical Partnerships

Drug donation programs for clinical trials
Shared data from company-sponsored studies
Public-private partnerships for trial execution

Patient Engagement

Patient advocacy group input on priorities
Recruitment support through patient networks
Outcome measure development with patient input

Notable Trials

NIH-Funded PD Clinical Trials

| Trial Name | Drug | Phase | N | Primary Outcome |
|------------|------|-------|---|-----------------|
| EXENATIDE-PD | Exenatide | Phase II | 60 | Motor scores |
| NILO-PD | Nilotinib | Phase II | 75 | Motor scores |
| AMBRA-PD | Ambroxol | Phase II | 120 | GBA activity |

Impact and Outcomes

Achievements

Advanced 15+ compounds into PD clinical trials
Established standardized protocols for repurposing screening
Created open-access database of preclinical results
Funded over $100M in PD clinical research

Challenges

Limited BBB penetration of some candidates
Optimal dosing for neuroprotection unclear
Biomarker development for target engagement
Patient selection for specific mechanisms

Future Directions

The program is expanding to include:

Precision Medicine Approaches: Genetic stratification (GBA, LRRK2, SNCA)
Combination Therapies: Multi-target approaches
Biomarker Development: Patient selection and response prediction
Prevention Trials: Pre-symptomatic intervention

References

Unknown, NINDS Parkinson's Disease Research Program (n.d.)

Unknown, NIH Clinical Trials for Parkinson's Disease (n.d.)

Unknown, Parkinson's Progression Markers Initiative (n.d.)

📖 View canonical wiki page →

NIH Parkinson's Disease Repurposing Program

Introduction

Overview

Introduction

Overview

Program Structure

NIH NINDS Leadership

NIH NIA Collaboration

Repurposing Pipeline

Phase I: Compound Identification

Phase II: Preclinical Validation

Phase III: Clinical Translation

Key Repurposed Drugs in Program

GLP-1 Receptor Agonists

Tyrosine Kinase Inhibitors

Anti-Inflammatory Agents

Collaboration Model

Academic Partnerships

Pharmaceutical Partnerships

Patient Engagement

Notable Trials

NIH-Funded PD Clinical Trials

Impact and Outcomes

Achievements

Challenges

Future Directions

See Also

References